AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Sage Therapeutics Q2 revenue at $23.2mln, up 68% YoY.
ByAinvest
Wednesday, Jul 30, 2025 4:12 pm ET1min read
• Sage Therapeutics reports $23.2mln ZURZUVAE revenue in Q2 2025, a 68% increase from Q1. • Cash, cash equivalents, and marketable securities at $366mln as of June 30, 2025. • Supernus Pharmaceuticals acquisition expected to close in Q3 2025.
Sage Therapeutics, Inc. (NASDAQ: SAGE) reported robust financial results for the second quarter of 2025, highlighting significant growth in revenue and a strong cash position. The biopharmaceutical company's latest earnings report indicates a 68% increase in revenue from ZURZUVAE, its oral treatment for postpartum depression (PPD), compared to the first quarter of 2025. This substantial growth was driven by increased investment, strong execution, and growing momentum behind the drug [2].The company generated $23.2 million in collaboration revenue from ZURZUVAE in the second quarter, representing a 68% increase from the first quarter of 2025. This revenue accounts for 50% of the net revenue Biogen records for ZURZUVAE in the U.S. Additionally, the company shipped over 4,000 prescriptions for ZURZUVAE, a 36% increase from the first quarter of 2025 [2].
Sage Therapeutics' cash position as of June 30, 2025, stood at $366 million, compared to $424 million at the end of the first quarter. The reduction in cash balances was primarily due to increased investments in ZURZUVAE and other research and development activities [2].
The company also announced a definitive agreement for Supernus Pharmaceuticals to acquire Sage Therapeutics for $8.50 per share in cash, plus a contingent value right (CVR) worth up to $3.50 per share. The transaction is expected to close in the third quarter of 2025 [2].
Sage Therapeutics' stock traded up 0.5% during trading hours on Friday, July 25, 2025, hitting $8.80. The company's fifty-day moving average price is $8.15, and its two-hundred-day moving average price is $7.60. The firm has a market capitalization of $551.06 million, a P/E ratio of -1.52, and a beta of 0.29 [1].
Analysts have mixed opinions on Sage Therapeutics' stock. Several analysts have issued "sell" ratings, while others maintain a "hold" rating. The stock currently has an average rating of "Hold" and an average target price of $8.23 [1].
References:
[1] https://www.marketbeat.com/instant-alerts/sage-therapeutics-sage-expected-to-announce-earnings-on-wednesday-2025-07-23/
[2] https://www.marketscreener.com/news/sage-therapeutics-announces-second-quarter-2025-financial-results-ce7c5fdfd081f426
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet